Genomics of Drug Sensitivity in Cancer

We have characterised 1000 human cancer cell lines and screened them with 100s of compounds.
On this website, you will find drug response data and genomic markers of sensitivity.

Overview

576,758

dose-response curves

722,057

genomic associations tested

Browse Compounds

Browse Cell Lines

Browse Cancer Features

Our website and results are part of an ongoing research project. These webpages are updated frequently and our results are not final or complete.

What's new?

Release 8.5 (October 2023)

Release 8.5 fixes a bug in the fitting of dose response curves in the GDSC2 dataset for 39 compounds where the concentration range differs between cell lines. IC50 values are highly correlated between releases 8.4 and 8.5 for the 14106 curves affected - a minimum Pearson correlation per compound of 0.888. Removing SN-38 from the dataset improves the minimum correlation to 0.995. The GDSC1 dataset remains unchanged from release 8.4.

Datasets

GDSC1	GDSC2
Age
from 2010 to 2015	✓ NEW
Size
970 Cell lines	969 Cell lines
403 Compounds	297 Compounds
333292 IC50s	243466 IC50s
Assay
Resazurin or Syto60	CellTitreGlo
Duration
72 hours	72 hours

Key Publications

Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.
Yang et al., (2013) Nucl. Acids Res. 41 (Database issue): D955 - D961. (PMID:23180760 )

A landscape of pharmacogenomic interactions in cancer
Iorio et al., (2016). Cell, Volume 166, Issue 3, 740 - 754 (PMID:27397505 )

Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett et al., (2012) Nature volume 483, pages 570 – 575 (PMID:27397505 )

Mailing List

To receive news and data release alert, please sign up Translation-announce

The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project at the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.

Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.
Please note: The data files are experimental and academic in nature and are not licensed or certified by any regulatory body. Genome Research Limited provides access to data files on an “as is” basis and excludes all warranties of any kind (express or implied).